Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2022 | Insulins | Research

Determinants of metabolic syndrome among patients attending diabetes clinics in two sub-urban hospitals: Bono Region, Ghana

Authors: Timothy Agandah Abagre, Delia Akosua Bandoh, Adolphina Addoley Addo-Lartey

Published in: BMC Cardiovascular Disorders | Issue 1/2022

Abstract

Background

Over 70% of individuals with type 2 diabetes mellitus (T2DM) may have metabolic syndrome in sub-Saharan Africa. Evidence about the prevalence, clustering, and determinants of metabolic syndrome components is needed to guide the implementation of interventions to prevent cardiovascular diseases in low-income countries.

Methods

A clinic-based cross-sectional study was conducted among 430 out-patients attending two-selected diabetes mellitus clinics in the Bono Region of Ghana. Data was collected in June 2016 among participants aged 30–79 years. The prevalence of metabolic syndrome was assessed using the harmonized definition. Patients were interviewed using semi-structured questionnaires and T2DM status was confirmed by reviewing medical records. The components of MS that were assessed included body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, triglycerides, high-density lipoprotein (HDL)-cholesterol, and blood glucose. Multiple logistic regression models were constructed to evaluate the risk factors of MS.

Results

The mean age of participants was 58.8 ± 11.49 years. The prevalence of MS was 68.6% (95% CI: 64.0–72.8), higher among women (76.3%, 95% CI: 70.6–81.2) than men (58.0%, 95% CI: 35.0–49.4) and in the 50–59-year age group (32.1%). The majority of participants [248 (57.7%)] had either two [124 (28.8%)] or four [124 (28.8%)] components of MS. Excluding fasting blood glucose (78.4%), the predominant components of MS identified in the study were reduced HDL cholesterol (70.2%), high waist circumference (60.9%), and elevated systolic blood pressure (49.8%). The study found that the odds of MS in women are 2.2-fold higher than in men (95% CI: 1.29–3.58, p = 0.003). Duration of T2DM (OR 5.2, 95% CI: 2.90–9.31, p < 0.001) and overweight status (OR 6.1, 95% CI: 3.70–10.07 p < 0.001) were also found to be significant determinants of MS.

Conclusions

Metabolic syndrome was common among patients attending routine diabetes mellitus clinics in sub-urban hospitals in the middle belt of Ghana. Significant factors associated with metabolic syndrome included being female, living with diabetes for more than five years, and being overweight. Nationwide advocacy for routine screening and prevention of the syndrome should be initiated to prevent cardiovascular disease and mortality in this vulnerable population.

Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–62. https://doi.org/10.1016/S0140-6736(05)67402-8.CrossRefPubMed

Batey LS, RD LS, Goff DC, Tortolero SR, Nichaman MZ, Chan W, et al. Summary measures of the insulin resistance syndrome are adverse among mexican-american versus non-hispanic white children : the corpus christi child heart study. Circulation. 1997;96(12):4319–25. https://doi.org/10.1161/01.CIR.96.12.4319.CrossRefPubMed

Potenza MV, Mechanick JI. The metabolic syndrome. Nutr Clin Pract. 2009;24(5):560–77. https://doi.org/10.1177/0884533609342436.CrossRefPubMed

Kalk WJ, Joffe BI. The metabolic syndrome, insulin resistance, and its surrogates in African and white subjects with type 2 diabetes in South Africa. Metab Syndr Relat Disord. 2008;6(4):247–55. https://doi.org/10.1089/met.2008.0003.CrossRefPubMed

Ipadeola A, Adeleye J. THE metabolic syndrome and accurate cardiovascular risk prediction in persons with type 2 diabetes mellitus. Diabetes Metab Syndr Clin Res Rev. 2016;10(1):7–12. https://doi.org/10.1016/j.dsx.2015.08.011.CrossRef

Nsiah K, Shang V, Boateng K, Mensah F. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int J Appl Basic Med Res. 2015;5(2):133. https://doi.org/10.4103/2229-516X.157170.CrossRefPubMedPubMedCentral

Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32. https://doi.org/10.1016/j.jacc.2010.05.034.CrossRefPubMed

Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403–14. https://doi.org/10.1016/j.jacc.2006.09.032.CrossRefPubMed

Bhatti GK, Bhadada SK, Vijayvergiya R, Mastana SS, Bhatti JS. Metabolic syndrome and risk of major coronary events among the urban diabetic patients: north indian diabetes and cardiovascular disease study—NIDCVD-2. J Diabetes Complicat. 2016;30(1):72–8. https://doi.org/10.1016/j.jdiacomp.2015.07.008.CrossRef

10.

Mangat C, Goel NK, Walia DK, Agarwal N, Sharma MK, Kaur J, et al. Metabolic syndrome: a challenging health issue in highly urbanized Union Territory of north India. Diabetol Metab Syndr. 2010;2:19. https://doi.org/10.1186/1758-5996-2-19.CrossRefPubMedPubMedCentral

11.

Cheung BMY, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep. 2012;14(2):160–6. https://doi.org/10.1007/s11883-012-0227-2.CrossRefPubMedPubMedCentral

12.

Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Söderberg S, Alberti KGMM, et al. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obes Silver Spring. 2008;16(12):2707–16. https://doi.org/10.1038/oby.2008.412.CrossRef

13.

Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–28. https://doi.org/10.1016/S0140-6736(05)66378-7.CrossRefPubMed

14.

Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med. 2010;77(5):511–23. https://doi.org/10.1002/msj.20212.CrossRefPubMed

15.

Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):139–43. https://doi.org/10.1097/MED.0b013e3283444b09.CrossRefPubMedPubMedCentral

16.

Alemany M. Relationship between energy dense diets and white adipose tissue inflammation in metabolic syndrome. Nutr Res. 2013;33(1):1–11. https://doi.org/10.1016/j.nutres.2012.11.013.CrossRefPubMed

17.

Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr. 2006;83(6):1237–47.CrossRef

18.

Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; and internatio. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed

19.

Vishnu A, Gurka MJ, DeBoer MD. The severity of the metabolic syndrome increases over time within individuals, independent of baseline metabolic syndrome status and medication use: the atherosclerosis risk in communities study. Atherosclerosis. 2015;243(1):278–85. https://doi.org/10.1016/j.atherosclerosis.2015.09.025.CrossRefPubMedPubMedCentral

20.

Wu T-W, Chan H-L, Hung C-L, Lu I-J, Wang S-D, Wang S-W, et al. Differential patterns of effects of age and sex on metabolic syndrome in Taiwan: implication for the inadequate internal consistency of the current criteria. Diabetes Res Clin Pract. 2014;105(2):239–44. https://doi.org/10.1016/j.diabres.2014.04.027.CrossRefPubMed

21.

Mak K-H, Ma S, Heng D, Tan C-E, Tai E-S, Topol EJ, et al. Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events. Am J Cardiol. 2007;100(2):227–33. https://doi.org/10.1016/j.amjcard.2007.02.090.CrossRefPubMed

22.

Mogre V, Salifu ZS, Abedandi R. Prevalence, components and associated demographic and lifestyle factors of the metabolic syndrome in type 2 diabetes mellitus. J Diabetes Metab Disord. 2014;13(1):80. https://doi.org/10.1186/2251-6581-13-80.CrossRefPubMedPubMedCentral

23.

Martin KA, Mani MV, Mani A. New targets to treat obesity and the metabolic syndrome. Eur J Pharmacol. 2015;763:64–74. https://doi.org/10.1016/j.ejphar.2015.03.093.CrossRefPubMedPubMedCentral

24.

Dunkley AJ, Charles K, Gray LJ, Camosso-Stefinovic J, Davies MJ, Khunti K. Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis. Diabetes Obes Metab. 2012;14(7):616–25. https://doi.org/10.1111/j.1463-1326.2012.01571.x.CrossRefPubMed

25.

Wannamethee SG, Shaper AG, Whincup PH. Modifiable lifestyle factors and the metabolic syndrome in older men: effects of lifestyle changes. J Am Geriatr Soc. 2006;54(12):1909–14. https://doi.org/10.1111/j.1532-5415.2006.00974.x.CrossRefPubMed

26.

Alvarez León EE, Henríquez P, Serra-Majem L. Mediterranean diet and metabolic syndrome: a cross-sectional study in the Canary Islands. Public Health Nutr. 2006;9(8A):1089–98. https://doi.org/10.1017/S1368980007668487.CrossRefPubMed

27.

Kiortsis DN, Simos YV. Mediterranean diet for the prevention and treatment of metabolic syndrome: is it worth it? Angiology. 2014;65(1):5–8. https://doi.org/10.1177/0003319712470866.CrossRefPubMed

28.

Bach-Faig A, Berry EM, Lairon D, Reguant J, Trichopoulou A, Dernini S, et al. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr. 2011;14(12A):2274–84. https://doi.org/10.1017/S1368980011002515.CrossRefPubMed

29.

Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, Basterra-Gortari FJ, Nuñez-Cordoba JM, Martinez-Gonzalez MA. Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. Diabetes Care. 2007;30(11):2957–9. https://doi.org/10.2337/dc07-1231.CrossRefPubMed

30.

Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial effects of a dietary approaches to stop hypertension eating plan on features of the metabolic syndrome. Diabetes Care. 2005;28(12):2823–31. https://doi.org/10.2337/diacare.28.12.2823.CrossRefPubMed

31.

Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the american heart association/national heart, lung, and blood institute/american diabetes association conference on scientific issues related to management. Circulation. 2004;109(4):551–6. https://doi.org/10.1161/01.CIR.0000112379.88385.67.CrossRefPubMed

32.

Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366(9491):1059–62. https://doi.org/10.1016/S0140-6736(05)67402-8.CrossRefPubMed

33.

Titty F-VK. Glycaemic control, dyslipidaemia and metabolic syndrome among recently diagnosed diabetes mellitus patients in tamale teaching hospital, Ghana . Le Contrôle Glycaemic, Dyslipidaemia le Syndr du Métabolisme parmi le Diabète Récemment Diagnostiqué les Patients Mellit dans Tamale l’Enseignement l’Hôpital, le Ghana. 2010;29(1):8–11.

34.

Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med. 1998;15(7):539–53. doi:https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

35.

University of Cambridge. Food frequency questionnaire. In: Fenland study. Cambridge; 2014. p. 1–26.

36.

Isezuo SA, Ezunu E. Demographic and clinical correlates of metabolic syndrome in Native African type-2 diabetic patients. J Natl Med Assoc. 2005;97(4):557–63.PubMedPubMedCentral

37.

Kengne AP, Limen SN, Sobngwi E, Djouogo CF, Nouedoui C. Metabolic syndrome in type 2 diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan Africans. Diabetol Metab Syndr. 2012;4(1):22. https://doi.org/10.1186/1758-5996-4-22.CrossRefPubMedPubMedCentral

38.

Pradhan AD. Sex differences in the metabolic syndrome: implications for cardiovascular health in women. Clin Chem. 2014;60(1):44–52. https://doi.org/10.1373/clinchem.2013.202549.CrossRefPubMed

39.

Pokharel DR, Khadka D, Sigdel M, Yadav NK, Acharya S, Kafle RC, et al. Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and Harmonized criteria. J Diabetes Metab Disord. 2014;13(1):1–13. https://doi.org/10.1186/s40200-014-0104-3.CrossRef

40.

Subramani SK, Mahajan S, Chauhan P, Yadav D, Mishra M, Pakkirisamy U, et al. Prevalence of metabolic syndrome in Gwalior region of Central India: a comparative study using NCEP ATP III, IDF and Harmonized criteria. Diabetes Metab Syndr Clin Res Rev. 2019;13(1):816–21. https://doi.org/10.1016/j.dsx.2018.12.003.CrossRef

41.

Tan MC, Ng OC, Wong TW, Joseph A, Chan YM, Hejar AR. Prevalence of metabolic syndrome in type 2 diabetic patients: A comparative study using WHO, NCEP ATP III IDF and Harmonized definitions. Health Irvine Calif. 2013;05(10):1689–96. https://doi.org/10.4236/health.2013.510227.CrossRef

42.

Ogbera AO, Deedwania P, Gupta R, Reaven G, Alberti K, Eckel R, et al. Prevalence and gender distribution of the metabolic syndrome. Diabetol Metab Syndr. 2010;2(1):1. https://doi.org/10.1186/1758-5996-2-1.CrossRefPubMedPubMedCentral

43.

Janghorbani M, Amini M. Incidence of metabolic syndrome and its risk factors among type 2 diabetes clinic attenders in Isfahan. Iran ISRN Endocrinol. 2012;63(5):372–80. https://doi.org/10.5402/2012/167318.CrossRef

44.

Hathur B, Basavegowda M, Kulkarni P, Ashok NC. Metabolic syndrome among diabetics and pre-diabetics of Jenu Kuruba tribe in Mysore district (JKDHS-2)—An evidence of metabolic abnormalities leading to increase in CVD’s among Jenu Kuruba tribal population. Diabetes Metab Syndr Clin Res Rev. 2015;9(4):205–9. https://doi.org/10.1016/j.dsx.2015.08.004.CrossRef

45.

Singla P, Bardoloi A, Parkash AA. Metabolic effects of obesity: a review. World J Diabetes. 2010;1(3):76–88. https://doi.org/10.4239/wjd.v1.i3.76.CrossRefPubMedPubMedCentral

46.

Després J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–7. https://doi.org/10.1038/nature05488.CrossRefPubMed

47.

Goodpaster BH, Krishnaswami S, Harris TB, Katsiaras A, Kritchevsky SB, Simonsick EM, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med. 2005;165(7):777–83. https://doi.org/10.1001/archinte.165.7.777.CrossRefPubMed

48.

Kuk JL, Ardern CI. Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care. 2010;33(11):2457–61. https://doi.org/10.2337/dc10-0942.CrossRefPubMedPubMedCentral

49.

Biadgo B, Melak T, Ambachew S, Baynes HW, Limenih MA, Jaleta KN, et al. The prevalence of metabolic syndrome and its components among type 2 diabetes mellitus patients at a tertiary hospital. Northwest Ethiop Ethiop J Health Sci. 2018;28(5):645–54. https://doi.org/10.4314/ejhs.v28i5.16.CrossRefPubMed

50.

Shimajiri Y, Tsunoda K, Furuta M, Kadoya Y, Yamada S, Nanjo K, et al. Prevalence of metabolic syndrome in Japanese type 2 diabetic patients and its significance for chronic vascular complications. Diabetes Res Clin Pract. 2008;79(2):310–7. https://doi.org/10.1016/j.diabres.2007.08.026.CrossRefPubMed

51.

Luk AOY, So WY, Ma RCW, Kong APS, Ozaki R, Ng VSW, et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes A 5-year prospective analysis of the Hong Kong diabetes registry. Diabetes Care. 2008;31(12):2357–61. https://doi.org/10.2337/dc08-0971.CrossRefPubMedPubMedCentral

52.

Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report. 2009;13:1–7.

53.

Yousefzadeh G, Sheikhvatan M. Age and gender differences in the clustering of metabolic syndrome combinations: a prospective cohort research from the Kerman Coronary Artery Disease Risk Study (KERCADRS). Diabetes Metab Syndr Clin Res Rev. 2015;9(4):337–42. https://doi.org/10.1016/j.dsx.2013.02.023.CrossRef

54.

Alshkri M, Elmehdawi R. Metabolic syndrome among type-2 diabetic patients in benghazi-libya: a pilot study. Libyan J Med. 2008;3(4):177–80. https://doi.org/10.4176/080715.CrossRefPubMedPubMedCentral

55.

Kelliny C, William J, Riesen W, Paccaud F, Bovet P. Metabolic syndrome according to different definitions in a rapidly developing country of the African region. Cardiovasc Diabetol. 2008;7(1):27. https://doi.org/10.1186/1475-2840-7-27.CrossRefPubMedPubMedCentral

56.

Dhanaraj E, Bhansali A, Jaggi S, Dutra P, Jain S, Tiwari P, et al. Prevalence and predictors of metabolic syndrome in non-obese Asian Indians with newly detected type 2 diabetes mellitus. J Indian Med Assoc. 2008;106(6):366–8.PubMed

57.

Alebiosu CO, Odusan BO. Metabolic syndrome in subjects with type-2 diabetes mellitus. J Natl Med Assoc. 2004;96(6):817–21.PubMedPubMedCentral

58.

Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008;26(10):1891–900. https://doi.org/10.1097/HJH.0b013e328302ca38.CrossRefPubMed

Title: Determinants of metabolic syndrome among patients attending diabetes clinics in two sub-urban hospitals: Bono Region, Ghana
Authors: Timothy Agandah Abagre
Delia Akosua Bandoh
Adolphina Addoley Addo-Lartey
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Insulins
Insulins
Type 2 Diabetes
Published in: BMC Cardiovascular Disorders / Issue 1/2022
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-022-02805-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Determinants of metabolic syndrome among patients attending diabetes clinics in two sub-urban hospitals: Bono Region, Ghana

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

The association between SYNTAX score and long-term outcomes in patients with unstable angina pectoris: a single-centre retrospective study

Correlation between atherogenic index of plasma and coronary artery disease in males of different ages: a retrospective study

Stable patients with suspected myocardial ischemia: comparison of machine-learning computed tomography-based fractional flow reserve and stress perfusion cardiovascular magnetic resonance imaging to detect myocardial ischemia

Severe coronary artery spasm during left atrial appendage closure plus catheter ablation for atrial fibrillation: case presentation

Clinical value and expression of Homer 1, homocysteine, S-adenosyl-l-homocysteine, fibroblast growth factors 23 in coronary heart disease

Prevalence of cardiovascular diseases and risk factors in adult patients with haemophilia: a cross-sectional study in a tertiary care hospital clinic in Sri Lanka

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page